Who to call at Allarity Therapeutics, and when

Fundz watches for the moments Allarity Therapeutics starts buying, and tells you who to reach.

An alert the day Allarity Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Allarity Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Allarity Therapeutics. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Allarity Therapeutics Enters Settlement Agreement with Novartis

Nov 02, 2026

Contract Type

settlement_agreement

BostonManufacturingBiotechnology

Description

On October 28, 2026, Allarity Therapeutics, Inc. entered into a Settlement and Release Agreement with Novartis Pharma AG regarding a liability of $4,900,000. The agreement stipulates a payment of $1,000,000 to Novartis, releasing both parties from related claims upon payment. This settlement resolves prior liabilities from a terminated license agreement.

Company Information

Company

Allarity Therapeutics

Location

24 SCHOOL STREET, 2ND FLOOR

Boston, Massachusetts, United States

About

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment.